JPRN-UMIN000033003
Recruiting
未知
Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study. - ctDNA for MRD with AML after transplant.KSGCT1702(ctDNA)
Kanto Study Group for Cell Therapy0 sites70 target enrollmentJune 15, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Sponsor
- Kanto Study Group for Cell Therapy
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Any patient who decline to register 2\.Any patient who are considered as inappropriate to register by attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
Active, not recruiting
Phase 1
CIRCULATE - A TRIAL TO IMPROVE CARE OF PATIENTS AFTER COLON TUMOR SURGERY, BASED ON AN INNOVATIVE MARKER: CIRCULATING TUMOR DNAstage II colon cancer, after tumour resectionTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-000935-15-FRCentre Hospitalier Universitaire (CHU) de Dijon1,980
Recruiting
Not Applicable
Circulating Tumour DNA in Stage 1 to 4 Ovarian CancerACTRN12617001119381Walter and Eliza Hall Institute of Medical Research100
Recruiting
Not Applicable
ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaEsophageal Squamous Cell CarcinomaNCT05426850Fudan University100
Active, not recruiting
Not Applicable
Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerStage II-III Gastric CancerNCT06157216Qilu Hospital of Shandong University85